Recent advances in understanding the biology of chronic lymphocytic leukemia (CLL) have resulted in the development of novel therapies targeting key signaling pathways involved in the pathogenesis of this disease.

Practical knowledge and skills are required to manage the needs of the growing patient population treated with ICIs, particularly as our understanding of best practices for addressing complex toxicities evolves.

Next generation sequencing methods are increasingly being utilized to match patients with targeted therapies.

The management of cancer is constantly evolving through the introduction of new developments related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care.

Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.

CAR T-cell therapy is associated with a novel toxicity profile with complex monitoring and supportive care requirements.

TLS is a potentially serious complication of anticancer therapy. If left untreated, its progression may cause acute kidney failure, cardiac arrhythmias, seizures, loss of muscle control, and death.